Quest, Labcorp Discuss PAMA and M&A with Investors

By Mark Terry | From the Volume XXXII, No. 13 – September 15, 2025 Issue

WHILE LAUDING EXCELLENT GROWTH FOR THE SECOND QUARTER, executives at Labcorp and Quest Diagnostics also expressed concern over the Protecting Access to Medicare Act (PAMA), which was passed by Congress in 2014 and which continues to cause uncertainty as full implementation is repeatedly…

Read More

---

An Insider’s Observances of Lab Outreach Deals

By R. Lewis Dark | From the Volume XXXII, No. 12 – August 25, 2025 Issue

THERE ARE MANY WAYS TO VIEW CLINICAL LABORATORY OUTREACH ACQUISITIONS and the enormous amount of money changing hands in these deals. From one point of view, those fearful of the continued expansion of national lab giants like Labcorp and Quest Diagnostics may shive…

Read More

---

At ADLM 2025, Spotlight Shines on Relationships

By Scott Wallask | From the Volume XXXII, No. 11 – August 4, 2025 Issue

CEO SUMMARY: At the ADLM conference, a new industry survey about the dynamic relationship between medical laboratories, physicians, and patients presented a strong argument for labs taking the lead in communicating and being more accessible to their colleagues. A troubleso…

Read More

---

News Briefs on Alzheimer’s Detection

By Scott Wallask | From the Volume XXXII, No. 9 – June 23, 2025 Issue

FDA-cleared IVD could replace scans There has been a significant amount of activity in recent weeks as it concerns tests to detect Alzheimer’s disease. Clinical labs and neuropathologists will want to keep a cl…

Read More

---

As 23andMe Faces Bankruptcy, Home Testing Shows Warts

By Robert Michel | From the Volume XXXII, No. 7 – May 12, 2025 Issue

HIGH-STAKES DRAMA SURROUNDING 23ANDME’S BANKRUPTCY—including CEO Anne Wojcicki resigning to try to bid for the company she cofounded and state prosecutors urging caution about the data privacy of the company’s customers—brings up a fundamental question regarding d…

Read More

---

Quest, Labcorp CEOs Discuss Tariff Strategies with Investors

By Robert Michel | From the Volume XXXII, No. 7 – May 12, 2025 Issue

Leaders at Labcorp and Quest Diagnostics indicated that they are prepared to weather at least the early months of the unfolding tariff war that is upending the global economy. “There will be some impact from …

Read More

---

May 12, 2025, Intelligence: Late-Breaking Lab News

By Robert Michel | From the Volume XXXII, No. 7 – May 12, 2025 Issue

Yet another clinical laboratory has sold off part of its services to a national commercial lab. Labcorp announced on April 21 that it had finalized its acquisition of North Mississippi Health Services’ (NMHS) ambulatory outreach laboratory business. A…

Read More

---

In the Past, Labs Used Courts to Thwart Feds

By Robert Michel | From the Volume XXXII, No. 6 – April 21, 2025 Issue

CEO SUMMARY: A federal judge’s recent decision to vacate the FDA’s final rule on laboratory developed tests harkens back to a 2008 case where clinical labs stopped a CMS competitive bidding project. In the earlier case, legal risks led the government to back down. The …

Read More

---

Quest Acquires ‘Select Assets’ of Fresenius Medical Care

By Robert Michel | From the Volume XXXII, No. 4 – March 10, 2025 Issue

FRESENIUS MEDICAL CARE AND QUEST DIAGNOSTICS AGREED TO A DEAL in which Quest will provide laboratory testing services for the latter’s dialysis clinics in the United States. Separately, Quest Diagnostics will acquire “select assets” of Spectra Labora…

Read More

---

Quest Diagnostics, Labcorp Issue Q4 and Full Year 2024 Earnings

By Robert Michel | From the Volume XXXII, No. 3 – February 17, 2025 Issue

LAB ACQUISITIONS IN 2024 WERE A CONTRIBUTING FACTOR TO REVENUE GROWTH at the nation’s two biggest clinical laboratory companies. This was reflected in the fourth quarter and full year 2024 earnings reports issued by Labcorp and Quest Diagnostics. Here are recently …

Read More

---